A Phase 1 interventional study of voclosporin ophthalmic solution in Keratoconjunctivitis Sicca, sponsored by Lux Biosciences, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-22.
Sponsored by Lux Biosciences, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Keratoconjunctivitis Sicca with a site in United States — none open to participants now, none under way, none of them phase 3. Keratoconjunctivitis Sicca · United States.
Among the 56 studies in Keratoconjunctivitis Sicca with a site in United States, this one is the 36th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2009, is one of 2 in phase 1, and was the 14th registered.
85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.
Browse Keratoconjunctivitis Sicca studies →None of the 56 studies in Keratoconjunctivitis Sicca with a site in United States is open now. The open studies under Keratoconjunctivitis Sicca, anywhere →
This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 16 · Phase 4 8
First in 1997; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 82 across 75 interventional studies indexed under Keratoconjunctivitis Sicca.
Median enrollment 100 across the 52 interventional studies, 203 across the 4 observational. Of the 54 that completed or were terminated, 26 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 56 have an industry lead sponsor. The 10 most frequent:
Lux Biosciences, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Lux Biosciences, Inc. has 1 study filed under Keratoconjunctivitis Sicca — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 56 studies in Keratoconjunctivitis Sicca with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LX214 ophthalmic solution 0.02%
Drug: voclosporin ophthalmic solution
Drug: voclosporin ophthalmic solution
placebo
Drug: voclosporin ophthalmic solution
0.02%, 0.2% t.i.d. or b.i.d.
ocular irritation
Time frame: 12 hours
The record gives a start of Feb 2009, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Lux Biosciences, Inc.